PEITC supplementation was able to decrease the expression levels of NF-κB, LOX-1, and COX-2, ameliorating obesity-induced inflammation via mTOR/PPARγ/AMPK signaling (mammalian target of rapamycin/peroxisome proliferator-activated receptor gamma/adenosine-monophosphate activated-protein kinase) [40,44]. The gene discussed is PPARG; the disease is Obesity.